EP Patent

EP2422781A1 — Resistance-repellent retroviral protease inhibitors

Assigned to Sequoia Pharmaceuticals Inc · Expires 2012-02-29 · 14y expired

What this patent protects

Resistance-repellent and multi-drug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

USPTO Abstract

Resistance-repellent and multi-drug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.

Drugs covered by this patent

Patent Metadata

Patent number
EP2422781A1
Jurisdiction
EP
Classification
—
Expires
2012-02-29
Drug substance claim
No
Drug product claim
No
Assignee
Sequoia Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.